Roche Reports Acceptance of sBLA from FDA for its Tecentriq (atezolizumab) + Abraxane (nab-paclitaxel) for 1L Metastatic Triple- Negative Breast Cancer (TNBC)

 Roche Reports Acceptance of sBLA from FDA for its Tecentriq (atezolizumab) + Abraxane (nab-paclitaxel) for 1L Metastatic Triple- Negative Breast Cancer (TNBC)

Shots:

  • The filling is based on the results of P-III IMpassion130 study, assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with 1L unresectable LA/M TNBC in ratio (1:1)
  • P-III IMpassion130 study results: mPFS (7.2 vs 5.5mos.); OS (25.0 vs 15.5mos.); no new safety signals, Presented at ESMO 2018. The expected FDA approval date for the combination therapy is 12 Mar, 2019
  • Tecentriq is a mAb binds with PD-L1 while blocking interaction with PD-1 and B7.1 receptor. Roche has 7 ongoing P-III trials for Tecentriq & has also received PR from FDA and is also approved by EU & FDA for metastaic NSCLC mUC in > 80 countries

Click Here to read full press release/ article | Ref: Roche | Image: Historias Roche

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post